IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 35M 70M 105M Q1 '14: 0 Q2 '14: 0 Q3 '14: 0 Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '23: 238K Q3 '23: 469K Q4 '23: 482K Q1 '24: 715K Q2 '24: 31.1M Q3 '24: 58.6M Q4 '24: 73.7M Q1 '25: 49.3M Q2 '25: 60M Q3 '25: 67.5M Q4 '25: 86.8M Q1 '26: 71.4M Q2 '26: 99.3M Q4 '14 Q1 '16 Q2 '17 Q3 '18 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

-20M 0 20M 40M 60M Q2 '23: -1.8M Q3 '23: -3.9M Q1 '24: -6.5M Q2 '24: -262K Q3 '24: 27M Q4 '24: 35.9M Q1 '25: 6.6M Q2 '25: 11.1M Q3 '25: 29M Q4 '25: 43.7M Q1 '26: 28.9M Q2 '26: 55.7M Q3 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q1 '10: -67.7K Q2 '10: -84.6K Q3 '10: -167K Q4 '10: -496.1K Q1 '11: -658.2K Q2 '11: -10.6M Q3 '11: -5.8M Q4 '11: -4.2M Q1 '12: -3.1M Q2 '12: -1.6M Q3 '12: -1.6M Q4 '12: -1.7M Q1 '13: -704.9K Q2 '13: -1M Q3 '13: -9.4M Q4 '13: -11.5M Q1 '14: -2.3M Q2 '14: -2.1M Q3 '14: -2.8M Q4 '14: -4.9M Q1 '15: -5.3M Q2 '15: -6.4M Q3 '15: -7.6M Q4 '15: -8.5M Q1 '16: -7M Q2 '16: -11.7M Q3 '16: -19M Q4 '16: -15.9M Q1 '17: -20.9M Q2 '17: -23.6M Q3 '17: -22.3M Q4 '17: -26.1M Q1 '18: -26.9M Q2 '18: -31.4M Q3 '18: -35.1M Q4 '18: -34.9M Q1 '19: -40M Q2 '19: -50.2M Q3 '19: -51.6M Q4 '19: -65.1M Q1 '20: -70.8M Q2 '20: -63.6M Q3 '20: -59M Q4 '20: -68.5M Q1 '21: -75.6M Q2 '21: -81.4M Q3 '21: -86.2M Q4 '21: -99.5M Q1 '22: -91.7M Q2 '22: -99.7M Q3 '22: -100.4M Q4 '22: -107M Q1 '23: -110.9M Q2 '23: -110.1M Q3 '23: -118.4M Q4 '23: -121.3M Q1 '24: -117.7M Q2 '24: -101.9M Q3 '24: -89.1M Q4 '24: -86.6M Q1 '25: -121.2M Q2 '25: -113.8M Q3 '25: -94.9M Q4 '25: -73.5M Q1 '26: -81M Q2 '26: -51.9M Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Net Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q1 '10: -67.7K Q2 '10: -84.6K Q3 '10: -713.8K Q4 '10: -741.9K Q1 '11: -564.3K Q2 '11: -11M Q3 '11: -5.8M Q4 '11: -8.4M Q1 '12: -5.8M Q2 '12: -327.3K Q3 '12: -673.9K Q1 '13: -1M Q2 '13: -3.4M Q3 '13: -9.4M Q4 '13: -11.5M Q1 '14: -2.3M Q2 '14: -2.1M Q3 '14: -2.8M Q4 '14: -4.7M Q1 '15: -5.3M Q2 '15: -6.4M Q3 '15: -7.6M Q4 '15: -8.4M Q1 '16: -6.9M Q2 '16: -11.6M Q3 '16: -18.8M Q4 '16: -15.7M Q1 '17: -20.7M Q2 '17: -23.4M Q3 '17: -22.1M Q4 '17: -25.9M Q1 '18: -26.5M Q2 '18: -30.7M Q3 '18: -33.8M Q4 '18: -32.6M Q1 '19: -37M Q2 '19: -47.6M Q3 '19: -49.5M Q4 '19: -63.6M Q1 '20: -69.6M Q2 '20: -63M Q3 '20: -58.6M Q4 '20: -68.4M Q1 '21: -75.4M Q2 '21: -81.4M Q3 '21: -86.1M Q4 '21: -99.3M Q1 '22: -91.6M Q2 '22: -99.3M Q3 '22: -99.6M Q4 '22: -105.3M Q1 '23: -107.4M Q2 '23: -106.5M Q3 '23: -113.8M Q4 '23: -116.4M Q1 '24: -113M Q2 '24: -97.1M Q3 '24: -83.5M Q4 '24: -78.6M Q1 '25: -116.2M Q2 '25: -111.7M Q3 '25: -91.3M Q4 '25: -71.9M Q1 '26: -79M Q2 '26: -47.3M Q2 '10 Q3 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Cost of Revenue Quarterly

0 20M 40M 60M Q2 '23: 2M Q3 '23: 4.3M Q1 '24: 7.3M Q2 '24: 31.4M Q3 '24: 31.5M Q4 '24: 37.8M Q1 '25: 42.7M Q2 '25: 48.9M Q3 '25: 38.5M Q4 '25: 43.1M Q1 '26: 42.5M Q2 '26: 43.6M Q3 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '10: -113.3K Q4 '10: -369.6K Q1 '11: -564.5K Q2 '11: -1.3M Q3 '11: -1.6M Q4 '11: -2.7M Q1 '12: -760.2K Q2 '12: -1.2M Q3 '12: -280.7K Q4 '12: 0 Q1 '13: -300K Q2 '13: -681.9K Q3 '13: -427.1K Q4 '13: -2.3M Q1 '14: -2.3M Q2 '14: -1.3M Q3 '14: -1.7M Q4 '14: 14M Q1 '15: 3.5M Q2 '15: -4.5M Q3 '15: -3.8M Q4 '15: -6.6M Q1 '16: -4.6M Q2 '16: -3.7M Q3 '16: -12.2M Q4 '16: -12.2M Q1 '17: -18.8M Q2 '17: -17.5M Q3 '17: -21.4M Q4 '17: -21M Q1 '18: -17.8M Q2 '18: -23.9M Q3 '18: -27.9M Q4 '18: -31.5M Q1 '19: -29.1M Q2 '19: -33.8M Q3 '19: -42.2M Q4 '19: -53.8M Q1 '20: -65.3M Q2 '20: -36.6M Q3 '20: -40.5M Q4 '20: -62.7M Q1 '21: -62.4M Q2 '21: -54M Q3 '21: -57.7M Q4 '21: -53.8M Q1 '22: -73.8M Q2 '22: -77.6M Q3 '22: -63.6M Q4 '22: -77.7M Q1 '23: -99.8M Q2 '23: -94M Q3 '23: -84.1M Q4 '23: -84M Q1 '24: -122.3M Q2 '24: -98.4M Q3 '24: -59M Q4 '24: -73.3M Q1 '25: -103.7M Q2 '25: -67.4M Q3 '25: -78.7M Q4 '25: -52.6M Q1 '26: -72.1M Q2 '26: -60.8M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '10: -113.3K Q1 '11: -564.5K Q2 '11: -1.3M Q3 '11: -1.7M Q4 '11: -2.8M Q1 '12: -760.2K Q2 '12: -1.2M Q3 '12: -280.7K Q4 '12: 0 Q1 '13: -300K Q2 '13: -681.9K Q3 '13: -439.8K Q4 '13: -2.3M Q1 '14: -2.3M Q2 '14: -1.3M Q3 '14: -1.9M Q4 '14: 12.5M Q1 '15: 2.7M Q2 '15: -4.6M Q3 '15: -3.9M Q4 '15: -6.7M Q1 '16: -4.6M Q2 '16: -3.8M Q3 '16: -12.9M Q4 '16: -12.9M Q1 '17: -19.6M Q2 '17: -17.5M Q3 '17: -21.7M Q1 '18: -17.9M Q2 '18: -24.3M Q3 '18: -28.4M Q4 '18: -31.8M Q1 '19: -29.9M Q2 '19: -35.2M Q3 '19: -43.4M Q4 '19: -57.2M Q1 '20: -65.9M Q2 '20: -41.6M Q3 '20: -58.4M Q4 '20: -86M Q1 '21: -73.1M Q2 '21: -63.6M Q3 '21: -67.4M Q4 '21: -61.4M Q1 '22: -85.2M Q2 '22: -82.2M Q3 '22: -65M Q4 '22: -80.7M Q1 '23: -105.5M Q2 '23: -103.5M Q3 '23: -87.7M Q4 '23: -87.5M Q1 '24: -126.5M Q2 '24: -98.9M Q3 '24: -61.3M Q4 '24: -77.5M Q1 '25: -109.9M Q2 '25: -74.9M Q3 '25: -89.5M Q4 '25: -61.9M Q1 '26: -78.7M Q2 '26: -66.3M Q1 '12 Q1 '14 Q1 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '20: 146.5K Q1 '21: 147.4K Q2 '21: 153.8M Q3 '21: 155.5M Q1 '22: 157.1M Q2 '22: 157.3M Q3 '22: 157.8M Q1 '23: 213.7M Q2 '23: 224.5K Q3 '23: 245.8K Q1 '24: 266.2K Q2 '24: 284.8K Q3 '24: 303.3K Q1 '25: 322.9K Q2 '25: 334.5K Q3 '25: 364K Q1 '26: 418.5K Q2 '26: 450.2K Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q4 '10: -0.02 Q1 '11: -0.03 Q2 '11: -0.18 Q3 '11: -0.24 Q4 '11: -0.34 Q1 '12: 7.06 Q2 '12: 7.21 Q3 '12: 6.42 Q4 '13: -7.63 Q1 '14: -6.46 Q2 '14: -2.36 Q3 '14: -1.81 Q4 '14: -0.48 Q1 '15: -0.51 Q2 '15: -0.56 Q3 '15: -0.61 Q4 '15: -0.61 Q1 '16: -0.61 Q2 '16: -0.70 Q3 '16: -1.69 Q4 '16: -1.77 Q1 '17: -1.96 Q2 '17: -2.10 Q3 '17: -1.30 Q4 '17: -1.41 Q1 '18: -1.39 Q2 '18: -1.36 Q3 '18: -1.37 Q4 '18: -1.28 Q1 '19: -1.27 Q2 '19: -1.31 Q3 '19: -1.35 Q4 '19: -1.58 Q1 '20: -1.83 Q2 '20: -1.92 Q1 '22: -2.29 Q2 '22: -2.39 Q3 '22: -2.47 Q4 '22: -2.48 Q1 '23: -2.40 Q4 '11 Q1 '14 Q2 '15 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q1 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.